A trace element solution comprises at least the following metals: zinc; manganese; selenium; and copper; and which comprises a concentration of the metals of at least 90 mg/ml. The solution may comprise the following concentrations: at least 60 mg/ml zinc; at least 10 mg/ml manganese; at least 5 mg/ml selenium; and at least 15 mg/ml copper. The solution may comprise chromium, iodine and chromium.

The present invention relates to the combination of PM01183 with several anticancer drugs, in particular other anticancer drugs selected from antitumor platinum coordination complexes, antimetabolites, mitotic inhibitors, anticancer antibiotics, topoisomerase I and/or II inhibitors, proteasome inhibitors, histone deacetylase inhibitors, nitrogen mustard alkylating agents, nitrosourea alkylating agents, nonclassical alkylating agents, estrogen antagonists, androgen antagonists, mTOR inhibitors, tyrosine kinase inhibitors, and other agents selected from aplidine, ET-743, PM02734 and PM00104, and the use of these combinations in the treatment of cancer.

The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one reacting group for reacting with a functional group on a protein, engineered protein, antibody, antibody fragment, peptide, agonist, antagonist, aptamer or ligand which may be capable of recognizing a selected target cell population, and/or derivatives/analogs/mimics thereof.

Disclosed are a pharmaceutical composition, cosmetic product, and food or drink product each comprising a porous ceramic obtained by combustion synthesis of a starting material comprising (1) titanium and (2) at least one member selected from the group consisting of carbon, boron, nitrogen, and silicon; a pharmaceutical composition and cosmetic product each comprising a radical- and nanobubble-containing liquid; and a blood treatment device comprising a blood flow channel for extracorporeal circulation of a patient's blood, the blood flow channel being provided with the porous ceramic above, and the porous ceramic and the blood are brought into contact with each other.

Disclosed are a pharmaceutical composition, cosmetic product, and food or drink product each comprising a porous ceramic obtained by combustion synthesis of a starting material comprising (1) titanium and (2) at least one member selected from the group consisting of carbon, boron, nitrogen, and silicon; a pharmaceutical composition and cosmetic product each comprising a radical- and nanobubble-containing liquid; and a blood treatment device comprising a blood flow channel for extracorporeal circulation of a patient's blood, the blood flow channel being provided with the porous ceramic above, and the porous ceramic and the blood are brought into contact with each other.

The invention relates generally to a formulation in which metal tungstate or metal molybdate particles are encapsulated within biocompatible, diseased cell-targeting polymeric coatings. Such formulations render metal tungstate or metal molybdate particles suitable for in vivo biomedical imaging and therapeutic applications.

A multidimensional nanoconstruct includes a three-dimensional thiolated protein, gelatin or polymer nanoparticle and exposed metallic nanoparticles bonded to outer surfaces of the particle. In a method of formation, number of metallic nanoparticles that attach to the carrier nanoparticle is controlled via microfluidics or via controlling the reactivity of the metallic nanoparticle and carrier nanoparticle.

A multidimensional nanoconstruct includes a three-dimensional thiolated protein, gelatin or polymer nanoparticle and exposed metallic nanoparticles bonded to outer surfaces of the particle. In a method of formation, number of metallic nanoparticles that attach to the carrier nanoparticle is controlled via microfluidics or via controlling the reactivity of the metallic nanoparticle and carrier nanoparticle.

The invention pertains to advances in real-time methods in nuclear magnetic resonance by offering a new dual-frequency dynamic nuclear polarization (DNP) method that uses a microwave beam to polarize the spins of electrons and concomitantly act as a NMR transmitter.

The invention pertains to advances in real-time methods in nuclear magnetic resonance by offering a new dual-frequency dynamic nuclear polarization (DNP) method that uses a microwave beam to polarize the spins of electrons and concomitantly act as a NMR transmitter.